Medication use and risk of amyotrophic lateral sclerosis: using machine learning for an exposome-wide screen of a large clinical database

References

• Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet. 2009;10:769–82.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
   PubMed Web of Science ®Google Scholar
• Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta. 2015;1852:679–84.
   PubMed Web of Science ®Google Scholar
• Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252–8.
   PubMedGoogle Scholar
• Zhang ZX, Anderson DW, Mantel N, Román GC. Motor neuron disease on Guam: temporal occurrence, 1941-85. Acta Neurol Scand. 1995;92:299–307.
   PubMed Web of Science ®Google Scholar
• Dickerson AS, Hansen J, Gredal O, Weisskopf MG. Amyotrophic lateral sclerosis and exposure to diesel exhaust in a Danish Cohort. Am J Epidemiol. 2018;187:1613–22.
   PubMed Web of Science ®Google Scholar
• Dickerson AS, Hansen J, Kioumourtzoglou MA, Specht AJ, Gredal O, Weisskopf MG. Study of occupation and amyotrophic lateral sclerosis in a Danish cohort. Occup Environ Med. 2018;75:630–8.
   PubMed Web of Science ®Google Scholar
• Factor-Litvak P, Al-Chalabi A, Ascherio A, Bradley W, Chío A, Garruto R, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(Suppl 1): 33–43.
   PubMedGoogle Scholar
• Heemskerk J. Screening Existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) Model. Retina. 2005;25:S56–S57.
   PubMedGoogle Scholar
• Heemskerk J, Tobin AJ, Ravina B. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat Neurosci. 2002;5: 1027–9.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:241–5.
   PubMed Web of Science ®Google Scholar
• Rudnicki SA. Estrogen replacement therapy in women with amyotrophic lateral sclerosis. J Neurol Sci. 1999;169:126–7.
   PubMed Web of Science ®Google Scholar
• Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology 2006;27:117–21.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3:413–7.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:235–45.
   PubMed Web of Science ®Google Scholar
• Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010;1–8.
   Google Scholar
• Moxey ED, O’Connor JP, Novielli KD, Teutsch S, Nash DB. Prescription drug use in the elderly: a descriptive analysis. Health Care Financ Rev. 2003;24:127–41.
   PubMedGoogle Scholar
• Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. Jama 2008;300:2867–78.
   PubMed Web of Science ®Google Scholar
• Kioumourtzoglou MA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:224–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Usher S, Ward K. Preparing for a U.S. National ALS Registry: lessons from a pilot project in the State of Georgia. Amyotroph Lateral Scler. 2011;12:130–5.
   PubMed Web of Science ®Google Scholar
• Rotem RS, Chodick G, Davidovitch M, Hauser R, Coull BA, Weisskopf MG. Congenital abnormalities of the male reproductive system and risk of autism spectrum disorders. Am J Epidemiol. 2018;187:656–63.
   PubMed Web of Science ®Google Scholar
• Peripherality Index of Local Authorities in Israel: Israel Central Bureau of Statistics; 2009. Accessed from: https://www.cbs.gov.il/en/publications/Pages/pw/Peripherality-Index-of-Local-Authorities-in-Israel-Combination-of-Potential-Accessibility-Index-with-Proximity-to-the-Tel.aspx.
   Google Scholar
• Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology 2016;47:76–81.
   PubMed Web of Science ®Google Scholar
• Yosef Y, Kiderman A, Chinitz D, Lahad A. The landscape of medical care consumption in Israel: a nationwide population cross-sectional study. Isr J Health Policy Res. 2022;11:38.
   PubMed Web of Science ®Google Scholar
• McGee G, Haneuse S, Coull BA, Weisskopf MG, Rotem RS. On the nature of informative presence bias in analyses of electronic health records. Epidemiology. 2022;33:105–13.
   PubMed Web of Science ®Google Scholar
• Organization WH. Anatomical Therapeutic Chemical (ATC) Classification 2022. Accessed from: https://www.who.int/tools/atc-ddd-toolkit/atc-classification#:∼:text=In%20the%20Anatomical%20Therapeutic%20Chemical,groups%20at%20five%20different%20levels.
   Google Scholar
• Chen T, Guestrin C, editors. Xgboost: a scalable tree boosting system. Proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining; 2016.
   Google Scholar
• Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; San Francisco, California, USA: Association for Computing Machinery; 2016. p. 785–94.
   Google Scholar
• Orfanoudaki A, Giannoutsou A, Hashim S, Bertsimas D, Hagberg RC. Machine learning models for mitral valve replacement: a comparative analysis with the Society of Thoracic Surgeons risk score. J Card Surg. 2021;37:18–28.
   PubMed Web of Science ®Google Scholar
• Lee SLS-I. A Unified Approach to Interpreting Model Predictions 2017. Accessed from: https://arxiv.org/abs/1705.07874.
   Google Scholar
• Mann RH. Impaired thiamine metabolism in amyotrophic lateral sclerosis and its potential treatment with benfotiamine: a case report and a review of the literature. Cureus 2023;15:e40511.
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Dean AF, Shaw CE, Al-Chalabi A, Mills KR, Leigh PN. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry. 2007;78:750–3.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Yamada K, Ono S, Ishibashi Y. Skin changes in patients with amyotrophic lateral sclerosis: light and electron microscopic observations. J Am Acad Dermatol. 1987;17:1006–12.
   PubMed Web of Science ®Google Scholar
• Qazi A, Malik F, Shafi L, Basar S, Qazi A. Young-onset amyotrophic lateral sclerosis with rare skin manifestation: case report and literature review. Cureus 2020;12:e7844.
   PubMed Web of Science ®Google Scholar
• Paré B, Touzel-Deschênes L, Lamontagne R, Lamarre M-S, Scott F-D, Khuong HT, et al. Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients. Acta Neuropathol Commun. 2015;3:5.
   PubMed Web of Science ®Google Scholar
• Clos AL, Kayed R, Lasagna-Reeves CA. Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol. 2012;3:5.
   PubMedGoogle Scholar
• Hemerková P, Vališ M. Role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis: antioxidant metalloenzymes and therapeutic strategies. Biomolecules 2021;11:437.
   PubMed Web of Science ®Google Scholar
• Wang H, O’Reilly ÉJ, Weisskopf MG, Logroscino G, McCullough ML, Schatzkin A, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011;173:595–602.
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112:649–60.
   PubMed Web of Science ®Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:9–18.
   PubMed Web of Science ®Google Scholar
• Zu T, Guo S, Bardhi O, Ryskamp DA, Li J, Khoramian Tusi S, et al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc Natl Acad Sci USA. 2020;117:18591–9.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Levy J, Dickerson AS, Paganoni S, Leventer-Roberts M. Statin medications and amyotrophic lateral sclerosis incidence and mortality. Am J Epidemiol. 2022;191:1248–57.
   PubMed Web of Science ®Google Scholar
• Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273:81–3.
   PubMed Web of Science ®Google Scholar
• Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine. 2021;100:e26751.
   PubMed Web of Science ®Google Scholar
• Nabizadeh F, Balabandian M, Sharafi AM, Ghaderi A, Rostami MR, Naser Moghadasi A. Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Acta Neurol Belg. 2022;122:979–86.
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)–a 20-year review: Can we do better? Amyotroph Lateral Scler. 2010;11:537–41.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:538–48.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, O’Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, et al. Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 2021;97:e1466-74–e1474.
   Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Mijajlović MD, Aleksić VM, Covičković Šternić NM. Cluster headache as a first manifestation of multiple sclerosis: case report and literature review. Neuropsychiatr Dis Treat. 2014;10:2269–74.
   PubMed Web of Science ®Google Scholar
• Gentile S, Ferrero M, Vaula G, Rainero I, Pinessi L. Cluster headache attacks and multiple sclerosis. J Headache Pain. 2007;8:245–7.
   PubMed Web of Science ®Google Scholar
• Singh N, Ray S, Srivastava A. Clinical mimickers of amyotrophic lateral sclerosis-conditions we cannot afford to miss. Ann Indian Acad Neurol. 2018;21:173–8.
   PubMed Web of Science ®Google Scholar
• Jia Z. Controlling the overfitting of heritability in genomic selection through cross validation. Sci Rep. 2017;7:13678–9.
   PubMed Web of Science ®Google Scholar
• Brodeur ZP, Herman JD, Steinschneider S. Bootstrap aggregation and cross‐validation methods to reduce overfitting in reservoir control policy search. Water Resour Res. 2020;56:184.
   Web of Science ®Google Scholar
• Wacholder S, Hartge P, Lubin JH, Dosemeci M. Non-differential misclassification and bias towards the null: a clarification. Occup Environ Med. 1995;52:557–8.
   PubMed Web of Science ®Google Scholar